 Mizuho upgraded Unity Biotechnology Inc NASDAQ: UBX to Buy from Neutral with a price target of 7, up from 5 after Unity announced longer-term Phase 1 data for UBX1325 in diabetic macular edema DME and wet age-related macular degeneration AMD. Analyst Salim Syed expects some investor sentiment shift to begin at this point for this underfollowed stock. 